MDxHealth SA (MDXH): Price and Financial Metrics

MDxHealth SA (MDXH): $7.86

0.09 (+1.09%)

POWR Rating

Component Grades













MDXH Stock Price Chart Interactive Chart >

Price chart for MDXH

MDXH Price/Volume Stats

Current price $7.86 52-week high $13.17
Prev. close $7.77 52-week low $6.76
Day low $7.64 Volume 1,500
Day high $7.86 Avg. volume 5,066
50-day MA $7.95 Dividend yield N/A
200-day MA $0.00 Market Cap 122.59M

MDxHealth SA (MDXH) Company Bio

MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDXH Latest News Stream

Event/Time News Detail
Loading, please wait...

MDXH Latest Social Stream

Loading social stream, please wait...

View Full MDXH Social Stream

Latest MDXH News From Around the Web

Below are the latest news stories about MDxHealth SA that investors may wish to consider to help them evaluate MDXH as an investment opportunity.

MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd

NEWS RELEASE 17 February 2022, 4:00 PM EST / 22:00 CET

GlobeNewswire | February 17, 2022

MDxHealth (MDXH) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

Rate - MDxHealth Downgraded to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of MDxHealth from a hold rating to a sell rating in a research report sent to investors on Friday morning, reports. According

Business Mag | February 12, 2022

MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NEWS RELEASE9 FEBRUARY 2022, 4:00 PM EST / 22:00 CET MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference IRVINE, CA, and HERSTAL, BELGIUM – February 9, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15-17, 2022. Michael K. McGarrity, CEO

Yahoo | February 9, 2022

MDxHealth Shareholder Transparency Declaration

NEWS RELEASE – REGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM – 10 December 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and

Yahoo | December 10, 2021

Read More 'MDXH' Stories Here

MDXH Price Returns

1-mo 0.13%
3-mo -9.76%
6-mo -21.79%
1-year N/A
3-year N/A
5-year N/A
YTD -17.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6763 seconds.